Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Botulinum Neurotoxin G (BoNT/G) is a highly potent neurotoxin produced by Clostridium botulinum. It is one of seven serotypes (A-G) of botulinum toxins. BoNT/G inhibits neurotransmitter release at neuromuscular junctions, leading to flaccid paralysis. The toxin consists of a light chain (LC) that cleaves SNARE proteins, specifically VAMP/synaptobrevin, and a heavy chain (HC) responsible for neuronal binding and translocation. It binds to gangliosides (like GD1a) and protein receptors (Synaptotagmin I) on presynaptic membranes. BoNT/G exists in complexes with non-toxic associated proteins (NAPs) that stabilize the toxin. Its mechanism of action involves binding, endocytosis, translocation of the LC, and cleavage of VAMP/synaptobrevin, ultimately blocking acetylcholine release.
BoNT/G binds to neuronal receptors (gangliosides like GD1a and Synaptotagmin I), is endocytosed, and translocates its light chain into the cytoplasm. The light chain then cleaves VAMP/synaptobrevin, a SNARE protein, preventing acetylcholine release and causing flaccid paralysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Botulinum Neurotoxin G (BoNT/G).